ReviewHeart international2022

Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.

Klevin Roger L Reyes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.